Advertisement

The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: Development and Psychometric Validation

Published:October 04, 2022DOI:https://doi.org/10.1016/j.jval.2022.08.004

      Abstract

      Objectives

      To facilitate the development of new therapies for Prader-Willi syndrome (PWS), we sought to develop a reliable and valid assessment of anxiousness and distress, common characteristics that have a significant negative impact on individuals with PWS and their families.

      Methods

      The PWS Anxiousness and Distress Behaviors Questionnaire (PADQ) was developed with extensive input from clinical experts, as well as caregivers of individuals with PWS, who participated in iterative sets of qualitative interviews. The psychometric properties of the PADQ were subsequently demonstrated in a cross-sectional evaluation using data from the Global PWS Registry provided by > 400 caregivers and confirmed using data from a phase 3 clinical trial of an oxytocin analogue (intranasal carbetocin, LV-101).

      Results

      Qualitative interview participants consistently endorsed the content of the PADQ and were confident they could accurately respond to each item based on their observations of their child’s behavior. Analysis of cross-sectional data supported the computation of a total PADQ score, as well as the reliability and validity of the measure. The results of analyses using longitudinal clinical trial data confirmed these properties and provided evidence for the responsiveness of the PADQ, further supporting its appropriateness for the evaluation of new treatments targeting anxiousness and distress in PWS.

      Conclusions

      The current body of evidence supports the conclusion that the PADQ measures observable behaviors that are meaningful to patients and their families and provides a valid and reliable method to assess beneficial treatment effects for some of the most challenging behaviors associated with PWS.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Driscoll D.J.
        • Miller J.L.
        • Schwartz S.
        • Cassidy S.
        Prader-Willi syndrome.
        in: Adam M. Ardinger H. Pagon R. GeneReviews. Seattle. University of Washington, Washington2017
        • Butler M.G.
        • Miller J.L.
        • Forster J.L.
        Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update.
        Curr Pediatr Rev. 2019; 15: 207-244
        • Schwartz L.
        • Caixas A.
        • Dimitropoulos A.
        • et al.
        Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium.
        J Neurodevel Dis. 2021; 13: 25
        • Feighan S.M.
        • Hughes M.
        • Maunder K.
        • Roche E.
        • Gallagher L.
        A profile of mental health and behaviour in Prader-Willi syndrome.
        J Intellect Disabil Res. 2020; 64: 158-169
        • Sinnema M.
        • Einfeld S.L.
        • Schrander-Stumpel C.T.
        • Maaskant M.A.
        • Boer H.
        • Curfs L.M.G.
        Behavioral phenotype in adults with Prader-Willi syndrome.
        Res Dev Disabil. 2011; 32: 604-612
        • Whittington J.
        • Holland A.
        Neurobehavioral phenotype in Prader-Willi syndrome.
        Am J Med Genet C. 2010; 154C: 438-447
        • Miller J.L.
        • Lynn C.H.
        • Driscoll D.C.
        • et al.
        Nutritional phases in Prader-Willi syndrome.
        Am J Med Genet A. 2011; 155A: 1040-1049
        • Whittington J.
        • Holland A.
        Cognition in people with Prader-Willi syndrome: insights into genetic influences on cognitive and social development.
        Neurosci Biobehav Rev. 2017; 72: 153-167
        • Dykens E.M.
        • Roof E.
        • Hunt-Hawkins H.
        • Daniell C.
        • Jurgensmeyer S.
        Profiles and trajectories of impaired social cognition in people with Prader-Willi syndrome.
        PLoS One. 2019; 14e0223162
        • Bohonowych J.
        • Miller J.
        • McCandless S.E.
        • Strong T.V.
        The global Prader-Willi syndrome registry: development, launch, and early demographics.
        Genes (Basel). 2019; 10: 713
      1. PWS registry data: anxiety in PWS [INFOGRAPHIC]. Foundation for Prader-Willi Research.
        • Kayadjanian N.
        • Vrana-Diaz C.J.
        • Bohonowych J.
        • et al.
        Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome.
        PLoS One. 2021; 16e0248739
        • Kayadjanian N.
        • Schwartz L.
        • Farrar E.
        • Comtois K.
        • Strong T.V.
        High levels of caregiver burden in Prader-Willi syndrome.
        PLoS One. 2018; 13e0194655
        • Skokauskas N.
        • Sweeny E.
        • Meehan J.
        • Gallagher L.
        Mental health problems in children with Prader Willi syndrome.
        J Can Acad Child Adolesc Psychiatry. 2012; 21: 194-203
        • Dykens E.M.
        • Roof E.
        • Hunt-Hawkins H.
        The cure for us is a lot of things: how young people with Prader-Willi syndrome view themselves and future clinical trials.
        A Appl Res Intellect Disabil. 2022; 35: 460-470
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders.
        5th ed. American Psychiatric Publishing, Arlington, Virginia2013
        • Tsai J.H.
        • Scheimann A.O.
        • McCandless S.E.
        • Strong T.V.
        • Bridges J.F.P.
        Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best–worst scaling.
        J Med Econ. 2018; 21: 1230-1237
        • Fehnel S.
        • Brown T.
        • Nelson L.
        • et al.
        Development of the Hyperphagia Questionnaire for use in Prader-Willi syndrome clinical trials.
        Value Health. 2015; 18: A2518
        • McCandless S.E.
        • Yanovski J.A.
        • Miller J.
        • et al.
        Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial.
        Diabetes Obes Metab. 2017; 19: 1751-1761
        • Cobo J.
        • Coronas R.
        • Pousa E.
        • et al.
        Multidimensional evaluation of awareness in Prader-Willi syndrome.
        J Clin Med. 2021; 10: 2007
        • Streiner D.L.
        • Norman G.R.
        Health Measurement Scales: a Practical Guide to Their Development and Use.
        2nd ed. Oxford University Press, New York, NY1995
        • McGraw K.O.
        • Wong S.P.
        Forming inferences about some intraclass correlation coefficients.
        Psychol Methods. 1996; 1: 30-46
        • Nunnally J.C.
        • Bernstein I.H.
        Psychometric Theory.
        3rd ed. McGraw-Hill, New York, NY1994
        • Scahill L.
        • Riddle M.A.
        • McSwiggin-Hardin M.
        • et al.
        Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity.
        J Am Acad Child Adolesc Psychiatry. 1997; 36: 844-852
        • Guy W.
        Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology, Revised.
        National Institute of Mental Health, Rockville, Rockville, MD1976
        • Walton M.K.
        • Powers 3rd, J.H.
        • Hobart J.
        • et al.
        Clinical outcome assessments: conceptual foundation—report of the ISPOR Clinical Outcomes Assessment – emerging good practices for outcomes research task force.
        Value Health. 2015; 18: 741-752
      2. Guidance for industry: patient reported outcome measures: use in medical product development to support labeling claims. US Food and Drug Administration.
        https://www.fda.gov/media/77832/download
        Date accessed: December 27, 2021